Elena Élez
0000-0002-9178-0246
Publication & Citation Trends
Publications
65 total
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
Cited by 147
OpenAlex
Encorafenib, Cetuximab, and mFOLFOX6 in <i>BRAF</i> -Mutated Colorectal Cancer PDF
Cited by 87
OpenAlex
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
Cited by 178
OpenAlex
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study.
Cited by 61
OpenAlex
ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer PDF
Cited by 92
OpenAlex
Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164
Cited by 85
OpenAlex
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study PDF
Cited by 854
OpenAlex
Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
Cited by 72
OpenAlex
Research Topics
Colorectal Cancer Treatments and Studies
(51)
Genetic factors in colorectal cancer
(36)
Cancer Immunotherapy and Biomarkers
(18)
Gastric Cancer Management and Outcomes
(10)
Colorectal Cancer Surgical Treatments
(8)
Affiliations
Universitat de Vic - Universitat Central de Catalunya
Hebron University
Universitat Autònoma de Barcelona
Sorbonne Université
Vall d'Hebron Institut de Recerca